M. James You, M.D., Ph.D.

(877) 460-4673
M. James You, M.D., Ph.D.
Pathologist
Clinical Expertise

Hematopathology

Academic Appointments
  • Dr. Norman & Melinda Payson Professorship
  • Professor and Chair, Department of Pathology
  • Professor, Hematologic Malignancies Translational Sciences, Beckman Research Institute

M. James You, M.D., Ph.D., is a professor and the Chair of the Department of Pathology at City of Hope® and a Professor in the Department of Hematologic Malignancies Translational Sciences at the Beckman Research Institute at City of Hope National Medical Center.

Dr. You is a distinguished physician-scientist, whose career encompasses significant contributions to cancer genetics, molecular hematopathology, and translational oncology. With more than two decades of experience, Dr. You is a renowned expert in the field of hematopathology. He has received numerous awards for his research and teaching, with more than 150 peer-reviewed articles to his name. Before joining City of Hope, he held multiple leadership positions at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr. You’s philosophy centers on connecting research insights to real-world care, treating every patient as an individual with unique physical, emotional and social needs and striving to provide more equitable access to cancer care for patients everywhere.

Board-certified in both anatomic pathology and hematology, Dr. You earned his medical degree at Zhejiang University School of Medicine in China and his Ph.D. at The University of Texas in Austin, Texas. He completed his postgraduate training at The University of Texas, Dana-Farber Cancer Institute/Harvard Medical School and Brigham and Women’s Hospital/Harvard Medical School.

His research focuses on modeling, mechanistic and translational studies of cancer. His research has advanced our understanding of tumor suppressor pathways, acute leukemias, lymphoma and the molecular mechanisms underlying hematologic malignancies.

Location

Education & Experience

Degrees

  • 1997, Ph.D., Molecular/Cellular Biology, The University of Texas at Austin, Austin, TX
  • 1989, M.S., Immunology, Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University), Shanghai, China
  • 1986, M.D., Zhejiang University School of Medicine (formerly known as Zhejiang Medical University), Zhejiang Province, China

Residency

  • 2004, Anatomic Pathology, Brigham and Women's Hospital / Harvard Medical School, Boston, MA

Fellowships

  • 2006, Pathology, Brigham and Women's Hospital / Harvard Medical School, Boston, MA
  • 2005, Hematopathology, Brigham and Women's Hospital / Harvard Medical School, Boston, MA
  • 2002, Postdoctoral Research Fellow, Cancer Genetics and Biology, Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA

Professional Experience

  • 2025-present, Department Chair, Department of Pathology City of Hope Cancer Center, Duarte, CA
  • 2025-present, Professor in the Department of Hematologic Malignancies Translational Sciences, Beckman Research Institute, City of Hope Duarte, Duarte, CA
  • 2018-2025, Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
  • 2012-2018, Associate Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Awards & Memberships

Awards

  • 2023-2024 Excellence in Teaching Award, The University of Texas MD Anderson Cancer Center, Department of Hematopathology, Division of Pathology and Laboratory Medicine
  • 2020 Clinic Research Award, The University of Texas MD Anderson Cancer Division of Pathology and Laboratory Medicine Excellence in Clinic Research
  • 2013 Research Award, Ladies Leukemia League
  • 2009 Research Award, Ladies Leukemia League
  • 2008–2024 Institutional Research Grant, American Cancer Society
  • 2008 Physician Scientist Award, The University of Texas MD Anderson Cancer Center
  • 2002–2005 Herbert M Karol Chair of Research, Brain Tumor Society
  • 2000–2002 NRSA Fellowship, NIH
  • 1999–2001 Research Fellowship Award, Brain Tumor Association, Genes Involved in Gliomagenesis
  • 1999 NRSA Fellowship, NIH
  • 1998 Professional Development Award, The University of Texas at Austin
  • 1996 Louis Sanger Foxhall Scholarship, The University of Texas at Austin
  • 1994 Orville Wyss Scholarship, The University of Texas at Austin

Memberships

  • American Society of Investigative Pathology
  • Society of Hematopathology
  • American Association for Cancer Research
  • American Society of Clinic Pathologist
  • American Society of Hematology
  • College of American Pathologists
  • Unites States and Canadian Academy of Pathology
  • American Association for the Advancement of Science
    Member

Publications

  • Xiong S, Zhang Y, Zhou X, Pant V, Mirani, Gencel-Augusto, Chau G, You MJ, Lozano G. Dependence on Mdm2 for Mdm4 inhibition of p53 activity. Cancer Lett. 2025 Jul 01; 621:217622. PMID: 40081463.
  • Lei G, Sun M, Cheng J, Ye R, Lu Z, Horbath A, Huo D, Wu S, Alapati A, Aggarwal S, Xu Z, Mao C, Yan Y, Yao J, Li Q, Chen X, Lee H, Zhuang L, Jiang D, Pataer A, Roth JA, Navin N, Koong AC, You MJ, Lin SH, Gan B. Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer Cell. 2025 Apr 07; S1535-6108(25):00132-1. PMID: 40215978.
  • Hong J, Sui P, Li Y, Xu KY, Lee JH, Wang J, Chen S, Zhang P, Wingate N, Noor A, Yuan Y, Hromas R, Zhou H, Hamamoto K, Su R, Yin CC, Ye F, Quesada AE, Chen J, Huang S, Zhou D, You MJ, Yang FC, Wang J, Xu M. PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell Stem Cell. 2025 Mar 06; 32(3):463-478. PMID: 39954676.
  • Kim DH, Medeiros LJ, Xu J, Tang GL, Qiu LQ, Wang SA, Chi OY, Yin CC, You MJ, Garces S, Lin P, Li SY. Diffuse Large B-Cell Lymphoma/High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements: a study of 60 Cases. Modern Pathology. 2025 Jan 11; 38(5) PMID: 39805522 https://doi.org/10.1016/j.modpat.2025.100710.
  • Ye M, Zuo Z, Kamata W, Ye FX, Yang YL, You MJ. Integrated Clinical Genotype-phenotype Characteristics of STAT3-mutated Myeloid Neoplasms. Clinic Cancer Research. 2024 Oct 15; 30(20):4681-4689. PMID: 38767620 https://doi.org/10.1158/1078-0432.CCR-24-0066.
  • Lei G, Mao C, Horbath AD, Yan Y, Cai S, Yao J, Jiang Y, Sun M, Liu X, Cheng J, Xu Z, Lee H, Li Q, Lu Z, Zhuang L, Chen MK, Alapati A, Yap TA, Hung MC, You MJ, Piwnica-Worms H, Gan B. BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. Cancer Discov. 2024 Aug 02; 14(8):1476-1495. PMID: 38552003.
  • Hu Z, Yin CC, Sun X, Han X, Wang W, Wang S, You MJ. A diagnostic dilemma for a patient with skin lesions and marked leukocytosis: mixed-phenotype acute leukemia or blastic plasmacytoid dendritic cell neoplasm with aberrant cytoplasmic CD3 expression? Pathology. 2025 Apr; 57(3):371-374. PMID: 39701847.
  • Yan, Y, Teng, H, Hang, Q, Kondiparthi, L, Lei, G, Horbath, A, Liu, X, Mao, C, Wu, S, Zhuang, L, You, MJ, Poyurovsky, MV, Ma, L, Olszewski, K, Gan, B. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nature communications. 2023 Dec 01; 14(1) PMID: 37339981 PMCID: PMC10281978.
  • Hong T, Li J, Guo L, Cavalier M, Wang T, Dou Y, DeLaFuente A, Fang S, Guzman A, Wohlan K, Kapadia C, Rosas C, Yang Y, Yin CC, Li S, You MJ, Cheng X, Goodell MA, Zhou Y, Huang Y. TET2 modulates spatial relocalization of heterochromatin in aged hematopoietic stem and progenitor cells. Nat Aging. 2023 Nov 01; 3(11):1387-1400. PMID: 37884767 PMCID: PMC11209854.
  • Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, Olszewski K, Horbath A, Chen X, Lei G, Mao C, Wu S, Zhuang L, Poyurovsky MV, You MJ, Hart T, Billadeau DD, Chen J, Gan B. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosi. Nat Cell Biol. 2023 Mar; 25(3):404. PMID: 36747082 PMCID: PMC10027392.
  • Lyu J, Liu Y, Gong L, Chen M, Madanat YF, Zhang Y, Cai F, Gu Z, Cao H, Kaphle P, Kim YJ, Kalkan FN, Stephens H, Dickerson KE, Ni M, Chen W, Patel P, Mims AS, Borate U, Burd A, Cai SF, Yin CC, You MJ, Chung SS, Collins RH, DeBerardinis RJ, Liu X, Xu J. Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. Cancer Discov. 2023 Jan 09; 13(1):170. PMID: 36222845 PMCID: PMC9827114.
  • Ye MT, Wang Y, Zuo Z, Calin S, He H, Tang Z, Jabbour EJ, Borthakur G, Zhang Y, Yang Y, You MJ. Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia. Cancer. 2023 Jan 01; 129(1):49-59. PMID: 36281717 https://doi.org/10.1002/cncr.34515.
  • Yu F, He H, Nastoupil LJ, Xu-Monette ZY, Pham K, Liang Y, Chen G, Fowler NH, Yin CC, Tan DF, Yang YL, Hu S, Young KH, Pham LV, You MJ. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. American Journal of Cancer Research. 2022 Oct 15; 12(10):4666-4679. PMID: 36381323.
  • Latchmansingh KA, Wang X, Verdun RE, Marques-Piubelli ML, Vega F, You MJ, Chapman J, Lossos IS. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage. Mod Pathol. 2022 Sep 01; 35(9):1220-1226. PMID: 35322192 PMCID: PMC9427670.
  • Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia. 2022 May; 36(5):1261-1273. PMID: 35173274 PMCID: PMC9061299. (Co-corresponding author)
  • Nguyen NT, Huang K, Zeng H, Jing J, Wang R, Fang S, Chen J, Liu X, Huang Z, You MJ, Rao A, Han G, Zhou Y. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nature Nanotechnology. 2021 Dec 16; 16(12):1424-1434. PMID: 34697491.
  • Ye MT, Wang Y, Wang SA, Pemmaraju N, Daver N, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2020 Apr; 61(4):963-966. PMID: 31750750.
  • Zhang Z, Jiang M, Borthakur G, Luan S, Huang X, Tang G, Xu Q, Ji D, Boyer AD, Li F, Huang R, You MJ. Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy. Am J Hematol. 2020 Feb; 95(2):E48-E51. PMID: 31769058.
  • Yuan T, Yang Y, Chen J, Li W, Li W, Zhang Q, Mi Y, Goswami RS, You JQ, Lin D, Qian MD, Calin S, Liang Y, Miranda RN, Calin GA, Zhou X, Ma L, Zweidler-McKay PA, Liu B, Weng AP, Medeiros LJ, Zhang Y, You MJ. Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. Leukemia. 2017 Nov;31(11):2355-2364. doi: 10.1038/leu.2017.80. Epub 2017 Mar 10. PMID: 28280276; PMCID: PMC5986278.
  • Zang S, Li J, Yang H, Zeng H, Han W, Zhang J, Lee M, Moczygemba M, Isgandarova S, Yang Y, Zhou Y, Rao A, You MJ, Sun D, Huang Y. Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis. J Clin Invest. 2017 Aug 01; 127(8):2998-3012. PMID: 28691928. (Co-corresponding author)